Abstract: Prevalence to the various biological activities of imidazo [4,5-b] pyridine nucleus has promoted us for an attempt of one pot synthesis of (1H, 3H) imidazo [4,5-b] 4-(2-methyl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-yl)benzene-1,3-diol (2f) were found potentially significant anti-tubercular agents (MIC=3.12 µg/mL). These compounds could be considered as promising leads over the Pyrazinamide (MIC= 3.125 µg/mL) and Streptomycin (MIC= 6.25 µg/mL). Present study could be a unique source for development of newer therapeutic agents in the treatment of infection by M. tuberculosis.
Introduction
Mycobacterium tuberculosis is one of the human pathogens responsible for causing eight million cases of new infections and two million human deaths every year in both developing and industrialized countries 1 . Treatment of the active forms of the disease has become increasingly difficult because of the growing antibiotic resistance of Mycobacterium tuberculosis. The elucidation of the complete genomes of Mycobacterium tuberculosis and the related Mycobacterium leprae has provided powerful tools for the development of novel drugs that are urgently required [2] [3] [4] . Both Mycobacterium tuberculosis and Mycobacterium RESEARCH ARTICLE leprae comprise complete sets of genes required for the biosynthesis of riboflavin (vitamin B2) involving catalytic step of Lumazine synthase. As the genome of Mycobacterium leprae has undergone a dramatic process of gene fragmentation, the fact that all riboflavin biosynthesis genes were retained in apparently functional form indicates that the biosynthetic pathway is of vital importance for the intracellular lifestyle of the pathogen. By extrapolation of this argument, it appears likely that the riboflavin pathway genes are also essential for Mycobacterium tuberculosis.
In particular, M. tuberculosis is reported for different inhibitors of Lumazine synthase by considering structural and thermodynamic insights into the binding mode 5 . Riboflavin biosynthesis path involving Lumazine synthase catalysis is reported for list of other microorganism like Bacillus subtilis 6 , Aquifex aeolicus 7 and Spinacia oleracea 8 , as an icosahedral capsid formed from 60 identical subunits (12 pentamers). In Saccharomyces cerevisiae 8 , Schizosaccharomyces pombe 9 , Brucella abortus 10 and Magnaporthe grisea 11 presence of homopentameric enzymes. Riboflavin (Vitamin B 2 ) is biosynthesized by plants and numerous microorganisms but not by animals, whereas animals obtain riboflavin from dietary sources. A rational approach to therapeutically useful antibiotics would be to selectively inhibit an enzyme present in a parasite but absent in the host. Inhibition of the bio-synthesis of riboflavin provides such a strategy, since pathogenic microorganisms synthesize their own riboflavin, whereas mammals obtain this vitamin through dietary sources.
Riboflavin biosynthesis is therefore would be an attractive target for the design and synthesis of new antibiotics against M. tuberculosis, which are urgently needed because pathogens are becoming drug resistant at an alarming rate. The imidazopyridine moiety is an important pharmacophore that has proven to be useful for a number of biologically relevant targets 12 . Imidazo [4,5-b] pyridine, known as 1-desasapurine, is a common structural motif found in numerous molecules that display antiviral, antifungal, antibacterial activities 13 . The potent biological activity and the prevalence of 1-desazapurines in both natural products and pharmaceuticals have inspired significant interest in the synthesis of these heterocycles. Compounds that belong to the imidazo [4,5-b] pyridin-2-one class have been shown to be nonsteroidal anti-inflammatory and analgesic agents [14] [15] [16] [17] and to possess antidepressant [15] [16] [17] [18] , antiphlogistic [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , cardiotonic [17] [18] [19] [20] , hypotensive and anti-arrhythmic activity [18] [19] [20] [21] . In addition certain members of this class had been reported to be a potent inhibitor of Aurora-A 22 , adenosine deaminase (ADA) inhibitors 23 , potent inhibitors of inosine 5'-monophosphate dehydrogenase (IMPDH) 24 . Recent studies from many laboratories, implicate the role of these scaffolds in the treatment of many of the most common human diseases, including diabetes 25 , cancers 26 and an array of neurological syndromes 27 .
In the present study, some possible derivatives of 1-desazopurines as (1H,3H) imidazo [4,5-b] pyridines were proposed and docked against Lumazine synthase enzyme from Mycobacterium tuberculosis (PDB 2C92). Different sets of interactions were measured in between title compounds and target protein Lumazine synthase. In-silico method is a huge breakthrough in the expensive and lengthy process of drug design and development. With the aim to move for anti-tubercular activity of selected scaffolds, we next arrive at in vitro anti-tubercular screening of test compounds by Microplate Alamar Blue Assay (MABA) method. Anti-tubercular standard compounds used in the assay were Pyrazinamide and Streptomycin. The result was measured and reported in the form of minimum inhibitory concentration (MIC), can be defined as lowest concentration of test compound required to prevent color change from blue to pink. Chem Sci Trans., 2015, 4(1), 1 -1 6
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Structures of all synthesized compounds were confirmed using 1 H NMR, 13 C NMR, FT-IR, mass spectroscopy and CHN analysis. Both the reactions reported (Scheme 1 and Scheme 2) are single step and one pot methods explaining reduction of energy, time and ultimately cost. MIC of tested compounds was stated in µg/ml demonstrated that number of the tested compounds showed good anti-tubercular activity as compared to standard drugs Pyrazinamide and Streptomycin. Comparison of output data of docking and MIC findings of in-vitro assay testing showed good results. Our aim is to propose (1H,3H) imidazo [4,5-b] pyridines as inhibitors of Lumazine synthase in M. tuberculosis could be potential lead compounds for the design of therapeutically useful antibiotics to eradicate multi drug resistant (MDR) and extensively drug resistant (XDR) strain of M. tuberculosis.
Materials and methods
All chemicals used were of research grade quality and purchased from S.D. Fine Chemicals Ltd., Mumbai, Loba Chemie, Bangalore. Melting points (°C) were determined using a Fischer-Jones melting point apparatus and are uncorrected. Microanalyses (CHNO and X=halogen) were performed at the microanalytical center, Pune University using Rapid analyser. Fourier Transform Infrared spectra (FT-IR, KBr cm -1 ), were run on JASCO 401 FT-IR spectrometer.
1 H and
13
C NMR spectra were recorded on BRUKER AVANCE II FT-NMR (400 MHz) using TMS as an internal standard (chemical shifts in δ, ppm), s=singlet, d=doublet, m=multiplet, bs=broad singlet. The relative integrals of peak areas agreed with those expected for the assigned structures. Mass spectra were recorded on WATERS Q-TOF Micromass (LC-MS), performed at SAIF, Punjab University, Chandigarh. TLC analysis was carried out on silica gel-protected aluminum sheets (Type 60 F 254, Merck) and the spots were detected under UV-Lamp at λ 254 nm.
Experimental
The crystal structures of the target protein was obtained from Protein Data Bank and saved in standard 3D coordinate format. The protein Data Bank (PDB) is a repository for 3-D structural data of proteins and nucleic acids. This database provides the 3-D structure of all the proteins by NMR or by X-ray crystallography. After conducting adequate literature review lumazine synthase of M. tuberculosis (PDB entry code 2C92), was selected as the target for the present study. Ligand preparation was done by drawing the structures using ChemSketch 12 and Chem Draw Ultra 7 in 2D and saved as MDL Molfile format. Further conversion of ligands to 3D format using VLife Engine tools of Vlifemds 4.3. Protein visualization was done by loading the structure in SWISS PDB Viewer. Further the energy minimization was performed by Vlifemds 4.3 software. Docking score for all test ligand was reported in Table 1 . Docking simulations were performed using Biopredicta tool in the grip docking mode. The number of docking run was set to 10. Different types of interactions were studied between docked 3D ligands and 3D macromolecule target. Standard compound Pyrazinamide (PYZ) was used for comparison of docking score and different types of interaction with the test ligands ( Figure 5-9 ).
General experimental procedure for the synthesis of compounds 1a-1k (Procedure A)
Mixture of 2 nitro 3 amino pyridine (1.0 mmol) and various aldehydes (1.0 mmol) was prepared in DMF (4 mL). It was further treated with 1 M aqueous Na 2 S 2 O 4 (3.0 mmol, 3 mL) subjected for heating the reaction mixture at 60 o C for 24 h. The reaction mixture was filtered to remove unreacted Na 2 S 2 O 4 and filterate was cooled to room temperature. Excess solvent was removed by high vacuum distillation. The concentrated residue formed was 4 Chem Sci Trans., 2015, 4(1), [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] washed with water (2×15 mL) and dried under reduced pressure to afford the desired product in satisfactory purity. Further recrystallization was carried using ethanol. Purified compounds were subjected for melting point and reaction progress was monitored with TLC and respective chemical test. 
1-(3H-Imidazo[4,5-b]pyridin-2-yl)butane-1,2,3,4-tetrol (1c)
This compound was obtained as gray solid (2.7 
2-(3H-Imidazo[4,5-b]pyridin-2-yl)phenol (1d)

4-(3H-Imidazo[4,5-b]pyridin-2-yl)phenol (1e)
This compound was obtained as gray solid (2.0 
4-(3H-Imidazo[4,5-b]pyridin-2-yl)-2-methoxyphenol (1f)
4-(3H-Imidazo[4,5-b]pyridin-2-yl)-N,N-dimethylaniline (1g)
This compound was obtained as yellow solid (1.5 
2-(4-Methoxyphenyl)-3H-imidazo[4,5-b]pyridine (1h)
This compound was obtained as gray solid (2.5 [4,5-b] 
2-(2-Nitrophenyl)-3H-imidazo
4-(3H-Imidazo[4,5-b]pyridin-2-yl)benzene-1,2-diol (1j)
This compound was obtained as greenish brown solid (1. [4,5-b] 28 and is presumably formed via formylation of the aniline nitrogen, nitro reduction and cyclization. Formylation of the aniline nitrogen is believed to assist nitro reduction. This approach has provided the shortest solid phase synthesis of imidazo pyridines to date. Since a wide range of amines and aldehydes are commercially available, a large number of pyridoimidazoles can be easily prepared using this method. [4,5- 
2-(2-Chlorophenyl)-3H-imidazo
4-Chloro-2-(2-methyl-2,3-dihydro-1H-imidazo
3-(aminomethyl)-4-(2-methyl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-l)benzene-1,2-diol (2c)
3-(2-Methyl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-yl)aniline (2d)
4-(2-Methyl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-yl)aniline (2e)
This compound was obtained as gray solid (1.25 
4-(2-Methyl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-yl)benzene-1,3-diol (2f)
4-(2-Methyl-2,3-dihydro-1H-imidazo[4,5-b]pyridin-2-yl)phenol (2g)
This compound was obtained as yellow solid (1.89 [4,5-b] [4,5-b] 
2-(4-Chlorophenyl)-2-methyl-2,3-dihydro-1H-imidazo
2-Methyl-2-phenyl-2,3-dihydro-1H-imidazo
In vitro anti-tubercular screening studies
Microplate alamar blue assay method
The anti-tubercular activity of the newly synthesized compounds was evaluated by micro plate Alamar Blue assay method (MABA) 29 . on bacterial strain M. tuberculosis H37 Rv ATCC (American Type Culture Collection), inoculums was grown on 100 mL of Middle brook 7H9 broth (Difco, Detroit Mich.) supplemented with 0.2% (v/v) glycerol, 10% (v/v) OADC (Oleic acid, albumin, dextrose, catalase, Difco) and 0.5% (v/v) Tween 80. The complete medium referred to as 7H9GC-T80. The Anti-TB susceptibility testing was performed in black, clear bottomed, 96-well microplates in order to minimize background fluorescence. Initial drug dilution was prepared in dimethyl sulfoxide and subsequent two fold dilutions were performed in 0.1 mL of 7H12 media in the micro plates.
The H37RV was diluted in 7H9 media to reach approximately 2x10 5 cfu/mL and 0.1 mL was added to wells. Wells containing compounds only were used to detect auto fluorescence of the compounds and were incubated at 37 o C. At day 7 of incubation, 20 μL of Alamar blue solution and 12.5 mL of 20% Tween 80 were added to all the wells and the plates were re-incubated at 37 o C for 24 h. A blue color in the well was interpreted as no bacterial growth, and pink color was scored as growth. The MIC was defined as lowest drug concentration which prevented the color change from blue to pink. The pyrazinamide and streptomycin were employed as standard drugs for the comparison of antitubercular activity and the results were tabulated in the Table 2, 3 .
Results and Discussion
In-silico docking experiment
An attempt for in silico design of title compounds aiming to inhibit lumazine synthase. Binding interaction of test motifs studied using crystal protein lumazine synthase from Mycobacterium tuberculosis (PDB 2C92) in complex with reference ligand Pyrazinamide (PYZ). With the aim of rationalizing the anti-tubercular activity, docking study was performed for the test ligand imidazo [4,5-b] pyridine 1a-1k and 2a-2j. Docking score for individual test ligand was reported in Table 1 . Possible binding interactions with target protein were studied ( Figure 5-9 ) and compared with the reference ligand PYZ. Best fit obtained from the group of test ligand was further studied for different types of binding interaction with the target protein.
Binding interactions of reference ligand PYZ were showed in Figure 2 
Chemistry
Previously one step method was reported for benzimidazole synthesis from o-nitro aniline and substituted aldehydes 30 . In the present one step synthesis of 3H imidazo [4,5-b] pyridines (1a-1k) successful attempt was made from different substituted aldehydes and 2-nitro-3-amino pyridine via reductive cyclisation using Na 2 S 2 O 4. Aqueous paste of Na 2 S 2 O 4 (1 M) was prepared in H 2 O and added in 3 equivalent proportion to the reaction mixture (cf. Figure 1, Scheme 1) .
Second reaction for one step synthesis of 1H imidazo [4,5-b] pyridine (2a-2j) was obtained from different substituted ketones and 2-nitro-3-amino pyridine via reductive cyclization using SnCl 2 .2H 2 O as reductive catalyst (cf. Figure 1, Scheme 2 ). This type of approach has been reported previously for obtaining benzimidazole motifs 31 . Imidazo pyridine scaffolds were visited after treatment of the substituted acetophenones and 2-nitro-3-amino pyridine with addition of SnCl 2 .H 2 O in presence of formic acid. It is presumably formed via formylation of the aniline nitrogen, nitro reduction and cyclization. Formylation of the aniline nitrogen is believed to assist nitro reduction, In summary, we have demonstrated that imidazo pyridines can be efficiently prepared from a support-bound 2 nitro 3 amino pyridine as like the same way benzimidazoles reported using a 'one-pot' reduction-cyclisation method. Both reactions were clear and without any form of side products or byproducts as impurities.
In vitro anti-tubercular screening
Alamar blue is an oxidation reduction dye used for screening of anti tubercular activity. The original oxidized form of alamar blue turns in to pink color upon reduction. Since M. tuberculosis is an aerobic organism during its growth turns alamar blue to pink. This technique has been used to predict the growth rise or inhibition of M. tuberculosis for testing anti-mycobacterial agents. Pink color indicates the presence of growth and blue color indicates the absence of growth [32] [33] [34] .
In vitro anti-mycobacterial testing was carried against M. tuberculosis (H37Rv). Results of anti-tubercular testing (MIC) were given in Table 2 and 3 indicated that varying degree of anti-mycobacterial activity was observed well interconnected with the structural variations of the synthesized compounds. Pyrazinamide and Streptomycin were the standard compounds used for in vitro testing of activity. However all the title compounds showed positive activity against M. tuberculosis (H37Rv) ranging from 3.125 to 25 µg/mL and predicted in terms of µM/mL x 10 -3 . Effect of various substituents of phenyl ring attached at 2 nd position of 1H imidazo [4,5-b] pyridine nucleus and nature of aliphatic and aromatic substituents attached at 2 nd position of 3H imidazo [4,5-b] pyridine nucleus have showed influence on activity. Descending order of activity was found to be as 1a, 1b, 1c, 1j, 2a, 2c and 2f (MIC=3.12 µg/mL) > 1d, 1e, 1g, 2a, 2e and 2j (MIC=6.25 µg/mL) > 1f, 1h, 2d, 2g and 2i (MIC=12.50 µg/mL) > 1i, 1k and 2h (MIC=25.00 µg/mL). Whereas MIC of Pyrazinamide observed was 3.125 µg/mL and for Streptomycin was 6.25 µg/mL. From the MIC output data of the anti-mycobacterial activity it was observed that compounds 1a, 1b, 1c, 1j, 2a, 2c and 2f were extremely active with observed MIC (3.125 µg/mL) equivalent to the standard drug Pyrazinamide(PYZ). These compounds could be selected as lead compounds and explored further to develop anti-mycobacterial agents.
Structural requirements for producing anti-mycobacterial activity is illustrated in Figure 10 . From the observed anti-tubercular activity of synthesized compounds 1H imidazo [4,5-b] pyridines and 3H imidazo [4,5-b] pyridines following SAR could be explained. 
Structure activity relationship for Anti-TB activity
Compounds with electron donating groups like OH, NH 2 showed potent activity. However such compounds with reduced lipophilicty, more polarizibility and greater electron donating power has reduced cytotoxicity and improved anti-tubercular activity. Compounds having to possess electron withdrawing groups like halogen (Cl) attached to the phenyl ring substituted at 2 nd position of imidazo [4,5-b] pyridine nucleus has comparative reduced activity.
Conclusion
In conclusion, we have synthesized series of 1H imidazo [4,5-b] pyridine and 3H imidazo [4,5-b] pyridine analogues with aim to screen in vitro anti-tubercular activity against M. tuberculosis (H37RV). Pyrazinamide and streptomycin were the standard drugs used in the activity. All the compounds tested showed positive response for anti-tubercular activity. Among the compounds tested 1a, 1b, 1c, 1j, 2a, 2c and 2f were found equally active to that of standard drug Pyrazinamide (MIC=3.12 µg/mL) and greater active than standard drug Streptomycin (MIC=6.25 µg/mL). Activity of these compounds may be because electron donating functional groups in their structure. Such compounds could be selected as promising leads to the standard drugs available against M. tuberculosis. Hopefully, series of synthesized title compounds would be a unique source for development of newer drugs in the treatment of multi drug resistant (MDR) and extensively drug resistant infection caused by M. tuberculosis.
